During Monday’s Current trade, Shares of Teradyne, Inc. (NYSE:TER), lost -0.03% to $18.35.
Teradyne, Inc. (TER) declared that it has accomplished the acquisition of Universal Robots, the leading supplier of collaborative robots; low-cost, easy-to-deploy and simple-to -program robots that work side by side with production workers to improve quality and enhance manufacturing efficiency. Collaborative robotics is a $100 million segment of the industrial robotics market growing at more than 50% per year.
Teradyne, Inc. provides automatic test equipment worldwide. The company’s Semiconductor Test segment designs, manufactures, sells, and supports semiconductor test products and services for wafer level and device package testing in automotive, industrial, communications, consumer, computer and electronic game applications, and others.
OHR Pharmaceutical Inc (NASDAQ:OHRP), during its Monday’s current trading session decreased -5.18% to $2.93.
Ohr Pharmaceutical, Inc. (OHRP), an ophthalmology research and development company, recently declared positive final results from a Phase II investigator sponsored clinical trial of OHR-102 (0.2% Squalamine lactate ophthalmic solution) in patients with macular edema secondary to branch (BRVO) and central retinal vein occlusion (CRVO). The results demonstrated that, following an initial 10 week combination therapy treatment period, patients who continued to receive a combination of topical OHR-102 BID plus Lucentis(R) achieved greater visual acuity gains than the control group who received Lucentis alone. At week 38, the mean gain in visual acuity from baseline for patients randomized (at week 10) to treatment with OHR-102 + Lucentis PRN was +27.8 letters contrast with +23.3 for patients randomized to treatment with Lucentis plus PRN alone (control group), a clinically meaningful difference of +4.5 letters. The data were presented by John Wroblewski, MD, a retina specialist at Cumberland Valley Retina Consultants on Saturday, July 11 at the 2015 Annual Meeting of the American Society of Retina Specialists (ASRS) in Vienna, Austria.
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes.
Finally, BorgWarner Inc. (NYSE:BWA), decreased -0.81%, to $50.45.
BorgWarner provides its award-winning regulated two-stage (R2S®) turbocharging technology for Volkswagen’s new high-performance diesel engine. Engineered to comply with the Euro 6 emissions standard, the 2.0-liter four-cylinder engine is the most powerful diesel engine in its class. Providing an output of 240 HP (176 kW) and a maximum torque of 369 lb.-ft. (500 Nm), it achieves an average fuel economy of 44 mpg (5.3 liters/100 km). Powered by BorgWarner’s optimized turbocharging technology, the diesel engine debuted in the VW Passat and sets new standards for efficiency and performance.
BorgWarner’s R2S turbocharging system comprises of two series-connected turbochargers and features a variable turbine geometry (VTG) turbocharger for the high-pressure stage combined with a larger B03 water-cooled turbocharger optimized for low-pressure exhaust gas recirculation (LP EGR). The low-pressure EGR is captured downstream of the exhaust emission control system and then mixed with the fresh air upstream of the compressor of the low-pressure stage. BorgWarner uses a special protective coating on the turbocharger compressor wheel to withstand the extreme loads and the corrosive particles. Controlled by an electric actuator, BorgWarner’s VTG turbocharger responds quickly at low engine speeds, resulting in a rapid rise in boost pressure for nearly instant acceleration. As the engine speed enhances, both turbochargers work together, gradually shifting to the larger, low-pressure turbocharger. At higher engine speeds, all of the gases flow directly to the larger B03 turbocharger, maintaining smooth power delivery at higher speeds. By combining two series-connected turbochargers of different sizes, BorgWarner’s R2S technology provides high boost pressures over the entire engine speed range.
BorgWarner Inc. manufactures and sells engineered automotive systems and components primarily for powertrain applications worldwide. The company’s Engine segment offers turbochargers, timing devices and chain products, emissions systems, thermal systems, and diesel coldstart and gasoline ignition technology. This segment also provides electric air pumps; turbo actuators; and exhaust gas recirculation coolers, tubes, and valves for gasoline and diesel applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
